Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | GSR | P00390 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | GRM8 | O00222 | 2/20 | 0.68 |
| ▸ | GRM6 | O15303 | 2/20 | 0.68 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.68 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.68 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.68 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.68 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.68 |
| ▸ | GRM5 | P41594 | 1/20 | 0.68 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.68 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.68 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.68 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.68 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.68 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamine SCHEMBL31436292 | 1.00 | KMT2A (1.00) | KMT2AALOX15BLMPMP22GSR | |
| Glutamine SCHEMBL711605 | 1.00 | KMT2A (1.00) | KMT2AALOX15BLMPMP22GSR | |
| Glutamine SCHEMBL7452 | 1.00 | KMT2A (1.00) | KMT2AALOX15BLMPMP22GSR | |
| Glutamine SCHEMBL411575 | 1.00 | KMT2A (1.00) | KMT2AALOX15BLMPMP22GSR | |
| Glutamine SCHEMBL411170 | 1.00 | KMT2A (1.00) | KMT2AALOX15BLMPMP22GSR | |
| Glutamine SCHEMBL5580393 | 1.00 | KMT2A (1.00) | KMT2AALOX15BLMPMP22GSR | |
| Glutamine SCHEMBL7453 | 1.00 | KMT2A (1.00) | KMT2AALOX15BLMPMP22GSR | |
| Glutamine SCHEMBL411588 | 1.00 | KMT2A (1.00) | KMT2AALOX15BLMPMP22GSR | |
| Glutamine SCHEMBL1332116 | 1.00 | KMT2A (1.00) | KMT2AALOX15BLMPMP22GSR | |
| Glutamine SCHEMBL31619675 | 1.00 | KMT2A (1.00) | KMT2AALOX15BLMPMP22GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8790897-B2 | Treatment of mucus hypersecretion | SYNTAXIN LTD. (GB) | 2014-07-29 | — | — | US | disclosed |
| EP-2449488-A1 | METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES | BIOCRATES Life Sciences AG (AT) | 2012-05-09 | — | — | EP | disclosed |
| US-7882838-B2 | Exothermic condom packaging | BLAISE HARRISON, LLC (US) | 2011-02-08 | — | — | US | disclosed |
| WO-2011000753-A1 | METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES | BIOCRATES LIFE SCIENCES AG (AT) | 2011-01-06 | — | — | WO | disclosed |
| US-20080249019-A1 | TREATMENT OF MUCUS HYPERSECRETION | SYNTAXIN, LTD. (GB) | 2008-10-09 | — | — | US | disclosed |
| US-7358241-B2 | Compositions and methods comprising farnesyl dibenzodiazepinones for treating neoplastic cells and conditions | THALLION PHARMACEUTICALS, INC. (CA) | 2008-04-15 | — | — | US | disclosed |
| US-20080032928-A1 | Treatment of mucus hypersecretion | SYNTAXIN LTD. | 2008-02-07 | — | — | US | disclosed |
| US-20060079508-A1 | Compositions and methods comprising farnesyl dibenzodiazepinones for treating neoplastic cells and conditions | ECOPIA BIOSCIENCES, INC. | 2006-04-13 | — | — | US | disclosed |
| US-20020137189-A1 | Cardiac hypertrophy factor and uses therefor | GENENTECH, INC. | 2002-09-26 | — | — | US | disclosed |
| US-5668253-A | POLYPEPTIDES AS ANTIGENS AND ANTIBODIES | HEALTH RESEARCH, INC. (US) | 1997-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079508-A1 | Compositions and methods comprising farnesyl dibenzodiazepinones for treating neoplastic cells and conditions | KRAS, MCL1, FNTB | KMT2A 3981/4885ALOX15 125/4885BLM 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.